Several US cannabis companies are confronting a series of class action lawsuits. Plaintiffs allege that these businesses exaggerated the therapeutic benefits of their products in marketing materials while failing to adequately warn consumers about potential mental health risks associated with cannabis use, such as schizophrenia, psychosis, anxiety, and suicidal tendencies.

The lawsuits have been filed in federal court in Illinois and state court in Connecticut. The defendants include some of the largest cannabis operators in the nation, such as Cresco Labs, Green Thumb, Verano Holdings, and Curaleaf. The complaints state that these companies marketed their products as cure-alls capable of treating insomnia, pain, anxiety, and even opioid addiction, creating a misleading impression that they were safe and therapeutic, despite allegedly knowing these claims lacked scientific backing.

Patrick Kennelly, a former McHenry County prosecutor and an attorney for the plaintiffs, highlighted that medical research has long established cannabis use can cause and exacerbate serious health conditions, including schizophrenia, psychosis, bipolar disorder, suicidal ideation, depression, and anxiety. Although Illinois law mandates product labels include warnings about potential cognitive impairment, the plaintiffs argue these cautions are insufficient and fail to communicate the more severe mental health risks.

A spokesperson for Curaleaf responded by stating the lawsuit was filed by attorneys associated with anti-cannabis organizations. Jack Franks, another attorney representing the plaintiffs, clarified that the lawsuit does not seek to shut down dispensaries but rather to compel retailers to warn consumers of potential dangers. The case requires court approval to proceed as a class action.